Triglyceride-glucose index and heart failure: a systematic review and meta-analysis

Cardiovascular Diabetology

Research

Amirhossein Sahebkar¹  Caterina Vinciguerra²  Alessandro Cannavo²  Sourena Sharifkashani³  Shaghayegh Khanmohammadi⁴  Amir Hossein Behnoush⁵  Amirmohammad Khalaji⁵  Kimiya Ghanbari Mardasi⁶ 

[1] Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;School of Medicine, The University of Western Australia, Perth, Australia;Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;Department of Translational Medicine Sciences, Federico II University of Naples, Naples, Italy;School of Medicine, Tehran University of Medical Sciences, Poursina St., Keshavarz Blvd., 1417613151, Tehran, Iran;School of Medicine, Tehran University of Medical Sciences, Poursina St., Keshavarz Blvd., 1417613151, Tehran, Iran;Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran;School of Medicine, Tehran University of Medical Sciences, Poursina St., Keshavarz Blvd., 1417613151, Tehran, Iran;Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran;Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran;Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran;

关键词: Heart failure;    Triglycerides;    Blood glucose;    Insulin resistance;    Systematic review;    Meta-analysis;   

DOI  :  10.1186/s12933-023-01973-7

 received in 2023-07-18, accepted in 2023-08-24,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundInsulin resistance (IR) is a major metabolic disorder observed in heart failure (HF) and is tightly associated with patients’ poor prognosis. The triglyceride-glucose index (TyG) has been proposed as a surrogate marker of IR in HF. Yet, whether TyG is a reliable clinical marker is still under debate. Hence, we aimed to respond to this relevant question via a systematic review and meta-analysis of existing studies.MethodsA systematic search was conducted in PubMed, Embase, Scopus, and Web of Science to find studies investigating the TyG index in patients with HF or its association with the incidence of HF. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) were pooled through random-effect meta-analysis. HRs were calculated using TyG as a continuous variable (1 unit increase) and by comparing the group with the highest TyG to the lowest TyG group.ResultsThirty studies, involving 772,809 participants, were included in this systematic review. Meta-analysis of seven studies comparing the highest-TyG to the lowest-TyG group showed a significantly increased risk of HF in the former group (HR 1.21, 95% CI 1.14 to 1.29, P < 0.01). The same result was found when pooling the HRs for a one-unit increase in the TyG index (HR 1.17, 95% CI 1.08 to 1.26). Similarly, a more elevated TyG index was associated with a higher incidence of HF in patients with type 2 diabetes or coronary artery disease. Additionally, the incidence of adverse events (readmission and mortality) in patients with HF was associated with TyG.ConclusionOur findings support the TyG index as a valuable marker to assess the risk of HF incidence in different populations and as a prognostic marker in patients with HF. Further studies should be conducted to confirm these associations and investigate the clinical utility of the TyG index.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1